[2-(4-氨基苯基)乙基]氨基甲酸叔丁酯 | 94838-59-2

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [2-(4-氨基苯基)乙基]氨基甲酸叔丁酯
• 中文别名: 4-[2-(BOC-氨基)乙基]苯胺；[2-(4-氨基苯基)乙基]丙二酸叔丁酯；4-[2-(Boc-氨基)乙基]苯胺
• 英文名称: tert-butyl 4-aminophenethylcarbamate
• 英文别名: [2-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester；tert-butyl N-[2-(4-aminophenyl)ethyl]carbamate；4-(N-boc-2-aminoethyl)aniline；2-(4-aminophenyl)ethylcarbamic acid 1,1-dimethylethyl ester
• CAS: 94838-59-2
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: HOPALBZGTWDOTL-UHFFFAOYSA-N

物化性质

• 熔点：
  71 - 73°C
• 沸点：
  396.8±25.0 °C(Predicted)
• 密度：
  1.077±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 海关编码：
  2924299090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: [2-(4-Amino-phenyl)-ethyl]-carbamic acid tert-butyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: [2-(4-Amino-phenyl)-ethyl]-carbamic acid tert-butyl ester
CAS number: 94838-59-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H20N2O2
Molecular weight: 236.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. ([2-(4-Amino-phenyl)-ethyl]-carbamic acid tert-butyl ester)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  [2-(4-氨基苯基)乙基]氨基甲酸叔丁酯 在 1-羟基苯并三唑 、 一水合肼 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 49.83h， 生成 米拉贝隆
  参考文献：
  名称：

  아미드 유도체의 제조방법

  摘要：

  This is a chemical formula and method for producing an amide derivative. The method includes the step of reacting chemical formula 2 and chemical formula 3 to produce a compound, and the step of reacting chemical formula 4 with the compound produced by the reaction.

  公开号：

  KR101868438B1
• 作为产物：
  描述：

  碳酸二叔丁酯 在 palladium on activated charcoal 氢气 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 反应 2.0h， 生成 [2-(4-氨基苯基)乙基]氨基甲酸叔丁酯
  参考文献：
  名称：

  Synthesis and evaluation of novel spermidine derivatives as targeted cancer chemotherapeutic agents

  摘要：

  The utility of the spermidine moiety as the homing device for the selective delivery of chemotherapeutic and diagnostic agents into cancer cells was explored. Two spermidine analogs containing a cytotoxic agent were synthesized, N-[3,4-bis(benzyloxy)phenethyl]-N(alpha)-(3-amino-propyl)-L-ornithinamide trihydrochloride, 1a and N-[4-[bis(2-chloroethyl)amino]phenethyl]-N(alpha)-(3-aminopropyl)-L-ornithinamide tetrahydrochloride, lb. These compounds were prepared from the fully protected spermidine molecule with a carboxyl group side chain, 8. The ability of the polyamine cytotoxic agents to inhibit B16-BL6 melanoma cell growth in culture was examined. The effects of pretreatment with DFMO on the activity of the synthesized compounds was also studied. The IC50 values of compounds la and lb were on the same order of magnitude as the control compounds, N-acetyldopamine and chlorambucil, respectively. The inhibitory activities of compounds la and lb were not enhanced by pretreatment with DFMO, suggesting that depletion of intracellular polyamines did not enhance the activity of these compounds.

  DOI：

  10.1021/jm00101a002
• 作为试剂：
  描述：

  2-(4-氨基苯)乙胺 、 、 二碳酸二叔丁酯 在 [2-(4-氨基苯基)乙基]氨基甲酸叔丁酯 作用下， 以 二氯甲烷 为溶剂， 生成 [2-(4-氨基苯基)乙基]氨基甲酸叔丁酯
  参考文献：
  名称：

  BRADYKININ B1 ANTAGONISTS

  摘要：

  本发明涉及公式(I)的化合物，其中R1、R1a、R1b、R2、R3和X、X1、X2、X3的含义如描述和权利要求中所述。所述化合物可用作Bradykinin B1拮抗剂。本发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。

  公开号：

  US20140073627A1

文献信息

• Thienopyrimidines useful as Aurora kinase inhibitors
  申请人：Lew Willard

  公开号：US20060035908A1

  公开（公告）日：2006-02-16

  The present invention provides compounds having the formula: wherein R 1 , R 2 , X 1 , X 2 , L 1 , L 2 , Y and Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下公式的化合物： 其中R1、R2、X1、X2、L1、L2、Y和Z的定义如本文中的类和子类中所定义，并且所述的药物组合物，如本文中一般描述和子类中描述的那样，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于治疗由Aurora介导的疾病。
• [EN] TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE TRIAZOLOTRIAZINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2A
  申请人：ZHEJIANG VIMGREEN PHARMACEUTICALS LTD

  公开号：WO2020002969A1

  公开（公告）日：2020-01-02

  The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.

  本发明提供了公式（1）的三唑三嗪衍生物作为A2A受体拮抗剂。公式（1）的化合物和包括这些化合物的药物组合物可用于治疗与A2A受体过度功能有关的疾病，如某些类型的癌症。该发明揭示了公式（1）的化合物和制备这些化合物的方法。
• [EN] PI-3 KINASE INHIBITOR PRODRUGS<br/>[FR] PROMEDICAMENTS D'INHIBITEURS DE PI-3 KINASE
  申请人：SEMAFORE PHARMACEUTICALS INC

  公开号：WO2004089925A1

  公开（公告）日：2004-10-21

  The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

  这项发明提供了PI-3激酶抑制剂的新型前药。这些新型化合物是LY294002及其类似物，包括可逆性季铵化胺。
• LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20180169262A1

  公开（公告）日：2018-06-21

  A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R 1 and R 2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.

  提供由式（I）表示的连接药物或其药学上可接受的盐或溶剂。在式（I）中，C是一个结合物，L是一个连接单元，D是一个毒素单元，n是一个从1到4的整数。结合物的结构由式（II）表示。在式（II）中，X是一个离去基团，R1和R2中的每一个独立地是一个单键或—NH—，Z是取代芳基、杂环芳基、直链烷基、环烷基、杂环烷基或它们的组合。抗体通过抗体的半胱氨酸残基与连接单元结合。还提供了使用上述连接药物的抗体-药物结合物（ADC）。
• [EN] NAMPT MODULATORS<br/>[FR] MODULATEURS DE NAMPT
  申请人：CYTOKINETICS INC

  公开号：WO2021159015A1

  公开（公告）日：2021-08-12

  Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

  提供了公式（II）的化合物或其药用可接受盐，其中R1、R2、R3、R4、R5、R6和p如本文所定义。还提供了包含公式（II）化合物或其药用可接受盐的药用可接受组合物。还提供了使用公式（II）化合物或其药用可接受盐的方法。